©2024 Stanford Medicine
Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma
Not Recruiting
Trial ID: NCT00352027
Purpose
The main purpose of this protocol is to estimate the percentage of patients with intermediate
risk Hodgkin lymphoma who will survive free of disease (Event-free survival) for three years
after treatment with multi-agent chemotherapy (Stanford V) and low-dose, tailored-field
radiation therapy. The hypothesis being studied is that this treatment will result in more
than 80% of patients being alive and free of disease three years after starting treatment.
Official Title
Stanford V Chemotherapy With Low-Dose Tailored-Field Radiation Therapy for Intermediate Risk Pediatric Hodgkin Lymphoma
Stanford Investigator(s)
Eligibility
Inclusion Criteria:
- Patient is less than or equal to 21 years of age
- Patient has a confirmed diagnosis of previously untreated Hodgkin lymphoma
- Has Ann Arbor stage IB, IIIA, or IA/IIA with extranodal extension, multiple nodal
involvement (3 or more sites), or bulky mediastinal adenopathy.
Exclusion Criteria:
- Patients with favorable risk features
- Patients with unfavorable risk features
- Patients who have received prior therapy for Hodgkin lymphoma.
Intervention(s):
procedure: Radiotherapy
drug: Adriamycin®
drug: Vinblastine
drug: Nitrogen Mustard
drug: Cyclophosphamide
drug: Vincristine
drug: Bleomycin
drug: Etoposide
drug: Prednisone
biological: G-CSF
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Peds Hem/Onc CRAs
650-723-5535